| Company* (Country; Symbol) |
University/ Nonprofit@ |
Type Of Agreement |
Product Area | Details (Date) |
| Accelr8 Technology Corp. (AMEX:AXK) | Washington University in St. Louis School of Medicine and methods the Denver Health and Hospital Authority | Research agreement | To identify antibiotic resistance mechanisms using Accelr8's patented analytical | The BACcel system will use the methods to speed the diagnosis of life-threatening infections in critically ill patients (1/3) |
| Addrenex Pharmaceuticals Inc.* | UNeMed Corp.(technology transfer arm of receptors the University of Nebraska Medical Center) | In-licensing agreement | For a library of nearly 400 compounds that target adrenergic | Addrenex agreed to pay milestones and future royalties on any product sales (12/28) |
| Agencourt Bioscience Corp.* | National Cancer Institute | Sequencing contract | To supply Agencourt with normal and cancer tumor tissue samples and periodic lists of genes and targeted regions to be sequenced | Agencourt will provide NCI collaborators working on cancer genomics research with a consistent high-throughput sequence resource; the term of the contract is one year, with an option to renew (11/13) |
| Alexion Pharmaceuticals Inc. (ALXN) | Oklahoma Medical Research Foundations | Agreement | To acquire all rights to certain patents related to complement- inhibition technology | Alexion will pay OMRF $10M, settling all claims filed between the parties (2/14) |
| Alimera Sciences Inc.* | Emory University | Agreement | To explore oxidative stress management, specifically the reduction of reactive oxygen species, as a treatment of ophthalmic diseases | The deal gives Alimera the exclusive option to license a class of small-molecule compounds called triphenylmethanes; Emory will receive milestone payments and royalties (2/26) |
| Alios BioPharma Inc.* | Cleveland Clinic | Exclusive worldwide license agreement | On the development of small-molecule RNase L activators for the treatment of viral diseases such as chronic hepatitis B and hepatitis C, HIV, influenza and others | Alios will provide the Cleveland Clinic with an up-front license fee, various development, regulatory and commercial milestones, and royalties on net sales (11/18) |
| AmVac AG* (Switzerland) | Max Planck Innovation GmbH (technology transfer agency of the Max Planck Society) | Licensing agreement | For rights to develop and commercialize a technology for the design and production of a new class of vaccines with improved safety and efficacy | Max Planck will receive up-front and milestone payments, as well as royalties and an equity stake in AmVac (12/12) |
| AmVac AG* (Switzerland) | Helmholtz Centre for Infection Research (Germany) | Licensing agreement | For exclusive rights to develop and commercialize a synthetic lipopeptide called MALP-2 and its derivatives as vaccine adjuvants | Helmholtz received up-front and milestone payments, as well as royalties and an equity stake in AmVac (12/12) |
| Aptagen LLC* | The ALS Therapy Development Institute | Research and development agreement | For Aptagen to use its own technology to develop aptabodies, synthetic molecular bullets designed to deliver a therapeutic compound to diseased cells | Aptagen's technology will be used as a research tool to expedite drug development in a mouse model of amyotrophic lateral sclerosis (1/7) |
| Arno Therapeutics Inc.* | Ohio State University | Worldwide, exclusive license agreement | For rights to commercially develop novel, orally available, targeted therapies for cancer | Arno acquired rights to several small molecules, including OSU-03012 and OSU-HDAC42 (1/28) |
| BG Medicine Inc.* | Copenhagen General Population Study | Research collaboration | To discover blood biomarkers that could help identify individuals at high risk for a heart attack | Further details were not disclosed (2/12) |
| BioLineRx Ltd. (Israel; TEL:BLRX) | Yissum, the technology transfer company of Hebrew University (Israel), and Hadasit, of Hadassah medical organization | Worldwide exclusive license agreement | For the development and commercialization of BL-4060, a small-molecule drug candidate to treat cancer | Financial terms were not disclosed (11/15) |
| BioTime Inc. (OTC BB:BTIM) | Wisconsin Alumni Research Foundation | Licensing agreement | For 173 patents and patent applications filed internationally relating to human embryonic stem cell technology created by James Thomson at the University of Wisconsin-Madison | BioTime's subsidiary, Embryome Sciences, plans to develop and commercialize a technology platform called Embryonics (1/9) |
| BT Pharma SA* (France) | Institut Pasteur (France) | Exclusive licensing agreement | For the adenylate cyclase vector technology | The patent claims a combination cancer treatment, which associates a chemotherapeutic agent with an immunotherapeutic agent (1/13) |
| Calibrant Biosystems Inc.* | Cleveland Clinic | Research collaboration | To use Calibrant's Gemini proteomics platform to identify protein networks and drug targets associated with glioblastoma multiforme | Financial terms were not disclosed (1/25) |
| Cancer Therapeutics CRC Pty Ltd. (Australia; OTC BB:CTHP) | Queensland Institute of Medical Research | Collaboration | To discover and develop new drugs to treat a variety of cancers based on the discovery of a new protein target that is critical to the genetic repair processes that promote cancer cell survival and keep them replicating | Terms were not disclosed (12/19) |
| Can-Fite BioPharma Ltd.* (Israel) | Rabin Medical Center (Israel) and the Center for Neurovirology and Cancer Biology at Philadelphia Temple University | Promotion agreement | For CF102, and to facilitate joint research to investigate the drug's effect on hepatitis C virus replication in hepatocytes, as well as to elucidate the molecular mechanisms underlying the anti-viral activity of CF102 | Financial terms were not disclosed (12/31) |
| CombinatoRx Inc. (CRXX) | Charley's Fund and the Nash Avery Foundation | Research collaboration | To identify disease-modifying, multi-targeted treatments for Duchenne muscular dystrophy | CombinatoRx will receive up to $3M in research funding to conduct drug discovery work and will own intellectual property and all rights to resulting product candidates (11/8) |
| Derma Sciences (OTC BB:DSCI) | University of Southern California | Exclusive licensing contract | For DSC127, a topical application for wound treatment in indications such as diabetic ulcers, leg ulcers associated with venous insufficiency, pressure ulcers and burns, as well as the reduction of scars related to surgical procedures | Derma will pay $840,000 up front, with certain regulatory and sales milestone payments and royalties; Derma will contribute between $4M and $5M to get the product through Phase II (11/5) |
| Diamyd Medical AB (Sweden; SSE:DIAMB) | U.S. National Institute of Diabetes and Digestive and Kidney Diseases | Clinical trial agreement | For a planned clinical study with the firm's Diamyd GAD-alum diabetes vaccine in 126 patients with new onset Type I diabetes | Diamyd Medical will supply the vaccine and placebo for the trial (11/26) |
| DOR BioPharma Inc. (OTC BB:DORB) | Walter Reed Army Institute of Research | CRADA | To provide additional means to characterize the immunogenic protein subunit component of the firm's ricin toxin vaccine RiVax | The RiVax development program has received $16M in grants (11/15) |
| Edgeline Holdings Inc. (OTC BB:ELHI) | Pharmaceutical Research Institute (Poland) | Exclusive worldwide option agreement | For patents covering the composition and use of Genistein analogues for cancer treatment | The technology involves compounds that appear to be novel antimicrotubule agents (2/27) |
| Egenix Inc.* | Harvard University | Licensing agreement | For patent rights covering technologies related to cancer therapy and prognostic testing | Financial terms were not disclosed (1/31) |
| Eucalyptus Ltd.* | Yissum Ltd.(Israel; arm of Hebrew University) | Licensing agreement | For an oral, small molecule for conditions such as neurodegenerative diseases | Yissum, together with technology transfer arms of Tel Aviv University and Clalit Health Services, will receive up-front payment, plus milestones and royalties (1/8) |
| Evotec AG (Germany; FSE:EVT) | CHDI Foundation Inc. | Extended collaboration | To support therapies for Huntington's disease | The extension will bring in an extra $37M in research funds (2/14) |
| Foamix Ltd.* | Ramot at Tel Aviv University Ltd. (Israel) | Licensing agreement | For exclusive rights to develop and commercialize Ramot's Organo-Boron compounds | The drugs are expected to be effective for onychomycosis (2/12) |
| Galapagos NV (Belgium; BR:GLPG) | Cystic Fibrosis Foundation Therapeutics Inc. | Collaboration | To discover new therapies for cystic fibrosis in a deal worth up to E5.5M ($8.1M) | It aims to identify small molecules derived from natural sources that improve the function of cystic fibrosis trans-membrane conductance regulator (11/29) |
| GeneGo Inc.* | Netherlands Toxicogenomics Center | Collaboration | To use toxicogenomics to develop highly predictive screens | The screens will evaluate chemical safety for human health, replacing, reducing or refining animal experiments, and improving the scientific basis of chemical risk assessment (2/13) |
| GeneGo Inc.* | Utrecht University in the Netherlands | Agreement | For MetaDrug, which is designed for predicting biological effects, such as indications, toxicity and off-target effects for new compound structures | The university will use it in its prestige master program for drug innovation (11/20) |
| GenVec Inc. (GNVC) | National Institute of Allergy and Infectious Disease Vaccine Research Center | Multiyear contract | To develop and manufacture novel adenovector-based HIV vaccines | The subcontract, begun in 2001, now extends through 2008, with a total value of $55M (10/19) |
| Genzyme Corp. (GENZ) | Moffitt Cancer Center | License agreement | To obtain exclusive worldwide diagnostic testing rights to the discovery of the relationship of two proteins to patient response to non-small-cell lung cancer treatment | Genzyme plans to develop and market a diagnostic test that can be used to measure the expression levels of the proteins in NSCLC patients (1/15) |
| Gilead Sciences Inc. (GILD) | Gladstone Institute of Virology and Immunology | Collaboration | To find HIV treatments based on the Vif protein | Gilead will provide research support and will pay royalty and milestone fees (1/13) |
| Glycart Biotechnology AG* (Switzerland) | Cancer Research Technology Ltd. (UK) | Agreement | For the rights to develop a preclinical antibody discovered by CRT | Glycart will use its GlycoMAB technology to enhance the efficacy of the antibody (1/22) |
| Glycominds Ltd.* (Israel) | Fox Chase Cancer Center | Research agreement | To collaborate on a breast cancer diagnostic blood test using Glycominds' anti-glycan antibodies biomarkers | Terms were not disclosed (10/25) |
| Helicos BioSciences Corp. (HLCS) | Victor Ambros at the University of Massachusetts Medical School's Program of Molecular Medicine | Collaboration | To develop an assay to characterize known species of microRNA and discover new noncoding RNAs | Terms were not disclosed (1/9) |
| Hemispherx Biopharma Inc. (AMEX:HEB) | Biken (arm of the Foundation of Microbial Disease of Osaka University) | Agreement | For the use of Ampligen as an immune enhancer to influenza vaccines | Hemispherx will receive both royalties and income for all Ampligen supplies used in on-going experimental work; financial terms were not disclosed (12/13) |
| Henderson Morley plc (UK; LSE:HML) | Australian Centre for Vaccine Development | Agreement | To jointly develop a vaccine targeted against cytomegalo-virus disease | The collaboration will use a combination of technologies from Henderson Morley and the center, with each party bearing its own development costs and sharing any new intellectual roperty (1/22) |
| ImmuneRegen BioSciences Inc.* | Lovelace Respiratory Research Institute | Agreement | To provide a broad range of product development services pertaining to inhalation and intranasal drug delivery, and associated regulatory affairs support | The agreement is expected to support ImmuneRegen's preparation for an investigational new drug application for Homspera to treat radiation sickness, influenza and severe acute respiratory syndrome (2/19) |
| ImmuPharma plc (UK; LSE:IMM) | Centre National de la Recherche Scientifique (France) | Worldwide development and commercialization agreement | For IPP-204106, a cancer drug | ImmuPharma plans to complete the formal preclinical development this year, with a Phase I trial expected to begin by year-end (1/8) |
| Implicit Bioscience* | Defense Threat Reduction Agency | Contract | To develop the immuno-modulator oglufanide disodium as a broad-spectrum therapeutic against potential biothreats | The contract is worth $16.3M (11/14) |
| Inhibitex Inc. (INHX) | Cardiff University (UK) and Katholieke Universiteit (Belgium) | Exclusive worldwide license agreement | For intellectual property covering a series of highly potent hepatitis C virus polymerase inhibitors | The deal includes an up-front license fee, future milestone payments and royalties on future net sales; the licensed compounds include a series of nucleoside analogues that inhibit NS5b, an RNA-dependent RNA polymerase that is a critical enzyme in the lifecycle of HCV (11/20) |
| InnerCool Therapies Inc. (unit of Cardium Therapeutics Inc.; AMEX:CXM) | University of Texas Health Science Center at Houston | Exclusive license agreement | For the development and commercialization of Caffeinol for acute ischemic stroke | Terms were not disclosed (10/22) |
| Innovative Biosensors Inc.* | University of Maryland | Partnership | To develop a miniaturized analysis system that could be used in industrial, environmental and clinical fields | The company will be working with A. James Clark School of Engineering at the university (2/25) |
|
Invitrogen Corp. (IVGN) |
University of Queensland | Licensing agreement | For a new type of microarray RNA chip | Terms were not disclosed (2/12) |
| Ipsen SA (France; PARIS:IPN) | Salk Institute for Biological Studies | Memorandum of understanding | To create the Ipsen Life Sciences Program at the institute | Core grants will support basic research on the role of chronic inflammation to malignant diseases such as cancer, loss of cognitive functions, movement disorders and metabolic syndromes (1/13) |
| Isis Pharmaceuticals Inc. (ISIS) | CHDI Inc. | Agreement | For the discovery and development of an antisense drug to treat Huntington's disease | Isis will receive up to $9.9M (10/26) |
| Juvaris BioThera-peutics Inc.* | Centers for Disease Control and Prevention | CRADA | To evaluate JVRS-100 adjuvanted H5N1 pandemic influenza vaccine | The aim is to confirm JVRS-100's ability to help induce a protective antibody response at low doses of H5N1 vaccine (1/15) |
| Living Cell Technologies Ltd.* (Australia) | Barbara David Center for Childhood Diabetes | Term sheet | To establish a diabetes clinical trial program in Denver | LCT and BDC collaboratively pursue regulatory approval and then conduct a U.S. trial in Type I diabetes with DiabeCell (2/27) |
| Medistem Laboratories Inc. (OTC BB:MDSM) | Institute of Cellular Medicine of the University of Newcastle (UK) | Modified agreement | Companies revised the royalty rate from 85% of ICM's pretax income to 20% of ICM's gross revenues | Terms were extended from 2010 to perpetuity, and Medistem was relieved of an obligation to fund ICM (1/7) |
| Metabolix Inc. (MBLX) | Donald Danforth Plant Science Center | Strategic research collaboration | To develop an advanced industrial oilseed crop to produce bioplastics | The collaboration is supported by a two-year, $1.14M grant from the Missouri Life Sciences Trust Fund (2/8) |
| Metabolon Inc.* | U.S. Army Medical Research Institute of Infectious Diseases | Contract | To use the firm's metabolomics platform to study the biochemical profiles of humans given the AVA anthrax vaccine | The AVA vaccine is the only FDA-licensed anthrax vaccine for humans (11/8) |
| Millennium Pharmaceuticals Inc. (MLNM) | Harvard Medical School's Office of Technology Development | Research collaboration | In the area of protein homeostasis | Harvard has granted Millennium a license to certain inventions and the two institutions will jointly advance the program in that cancer biology area over several years (1/31) |
| Morphotek Inc. (subsidiary of Eisai Co. Ltd.; FSE:EII) | National Cancer Institute | CRADA | For development of therapeutic antibodies to a cancer-associated protein identified by NCI researchers | Morphotek will apply its Morphodoma antibody technology to the development of therapeutic antibodies for the treatment of prostate cancer (1/9) |
| Morphotek Inc.* (subsidiary of Eisai Co.Ltd.; FSE:EII) | Ludwig Institute for Cancer Research (Switzerland) | Multiyear agreement | To fund the research to develop model systems that can validate the role of novel pathways for human disease and conduct preclinical proof-of-concept studies to demonstrate the feasibility of employing antibodies to block those disease pathways | Further terms were not disclosed (1/15) |
| NanoViricides Inc. (OTC BB:NNVC) | U.S. Army Medical Research Institute of Infectious Diseases | Material transfer agreement | To test the efficacy of several NanoViricides antiviral nanomedicines against hemorrhagic fever viruses at the Ft. Detrick, Md., BSL4 facilities | Terms were not disclosed (10/29) |
| Nara Biosciences Inc.* | Boston University | Licensing agreement | For the genetically engineered MyoMouse for developing therapies for muscle wasting disorders and diseases of aging | The license includes all commercial rights to therapeutic factors discovered using the MyoMouse (2/7) |
| Neuralstem Inc. (AMEX:CUR) | University of California, San Diego | Exclusive, worldwide licensing agreement | To the university's Spinal Multisegmental Cell and Drug Delivery System | Neuralstem gains the rights to all fields of use and the ability to grant sublicenses; the deal calls for UCSD to receive undisclosed milestone payments and royalties; Neuralstem will assume the cost of develoment, manufacture and approval of the product (11/20) |
| Neuralstem Inc. (AMEX:CUR) | University of Pennsylvania | Clinical trial research agreement | To treat patients suffering from ischemic spastic paraplegia | Terms were not disclosed (12/17) |
| Neurobiological Technologies Inc. (NTII) | Buck Institute for Age Research | Partnership | To develop a drug to treat Huntington's disease using fibroblast growth factor-2 | Further terms were not disclosed (12/3) |
| Optherion Inc.* | University of Pittsburgh | Licensing agreement | For worldwide rights to develop diagnostic products for age-related macular degeneration associated with specific variations on chromosome 10 | Financial terms were not disclosed (10/23) |
| Osiris Therapeutics Inc. (OSIR) | Department of Defense | Contract | To develop its mesenchymal stem cell therapy Prochymal to treat gastrointestinal injuries resulting from radiation exposure | The deal is potentially worth $224.7M, including $24.7M to cover the future development costs of Prochymal; the DoD has agreed to buy up to 20,000 doses at $10,000 per dose, or $200M total (1/4) |
| Osmetech plc (UK; LSE:OMH) | Marshfield Clinic | Licensing agreement | For a new warfarin biomarker discovered at Marshfield | It will be used to develop and market a genetic test that will more accurately determine the initial level of warfarin, an anti-coagulant, that should be prescribed to individual patients (11/4) |
| Oxford BioMedica (UK; LSE:OXB) | Carnegie Institution of Washington and the University of Massachusetts Medical School | License agreement | Granting the company rights to RNA interference technology | The rights are exclusive for RNAi gene silencing using lenti-viral vector technology for human gene therapy applications; Oxford BioMedica will make an undisclosed up-front payment, milestone payments and royalties on sales (1/7) |
| Perlegen Sciences Inc.* | SC Liver Research Consortium | Collaboration | To discover genetic variations aimed at predicting which hepatitis C patients are most likely to benefit from treatment | The parties will conduct large-scale genetic studies on samples from hundreds of patients with HCV who have been treated with interferon-alpha and ribavirin, both successfully and unsuccessfully (2/19) |
| Pharmasset Inc. (VRUS) | University of Cincinnati's Genome Research Institute | Research collaboration | Granting Pharmasset access to a library of 250,000 compounds and commercial rights to any lead compounds identified for HBV, HIV and HCV | Pharmasset will make an annual payment to the university, cover all development expenses and pay milestones and royalties (10/31) |
| Pipex Pharmaceuticals Inc. (AMEX:PP) | Veterans Affairs Medical Center | CRADA | To conduct preclinical studies of Coprexa in Huntington's disease | Further terms were not disclosed (11/26) |
| Plasticell* (UK) | King's College London | Agreement | To exploit and market two human embryonic stem cell lines | The agreement gives Plasticell a license to make, have made, use and sell the hESC lines KCL-001 and KCL-002 (2/13) |
|
Pro-Pharmaceuticals Inc. (AMEX:PRW) |
University of Massachusetts Lowell |
Research collaboration |
To evaluate Davanat in combination with chemotherapy drugs |
Terms were not disclosed (12/12) |
| PTC Therapeutics Inc.* | Spinal Muscular Atrophy Foundation | Expanded research collaboration | To identify and characterize compounds that have the potential to treat SMA by increasing production of the survival motor neuron protein, the absence of which causes SMA | Further terms were not disclosed(12/6) |
| Quantum Genomics Corp.* | Inserm, the French national institute for health and medical research, and Universities Paris Descartes and Paris XII Val-de-Marne | Partnership | To co-develop QGC002 as a treatment for stroke and cardiac ischemia | QGC is retaining the right to acquire the intellectual property generated by Inserm and to exploit associated know-how (1/24) |
| Quest PharmaTech Inc. (Canada; CDNX:QPT) | BC Cancer Agency | Collaboration | To develop a combination therapy for lung cancer using SL052 with various immunotherapeutic agents | BCCA will investigate therapeutic and mechanistic aspects of antitumor effects achieved by combining photodynamic therapy based on Quest's photo sensitizer with immuno-therapies (1/28) |
| Regenetech Inc.* | Johns Hopkins University | Sponsored research agreement | For a Type I diabetes treatment | Further details were not disclosed (11/14) |
| Rosetta Genomics Ltd. (Israel; ROSG) | Columbia University Medical Center | Collaboration | To develop microRNA-based diagnostic tests for multiple types of non-Hodgkin's lymphoma | Terms were not disclosed (12/13) |
| Rosetta Genomics Ltd. (Israel; ROSG) | Henry Ford Health System | Collaboration | To develop microRNA-based diagnostics and prognostics for brain cancer | The parties will analyze human brain tumors to identify unique microRNA biomarkers that have diagnostic and prognostic potential (1/14) |
| Rosetta Genomics Ltd. (Israel; ROSG) | New York University School of Medicine | Expanded collaboration | To screen for specific microRNA biomarkers and signatures that may be used to diagnose and target congenital heart disease in newborns | Further terms were not disclosed(11/20) |
| Samaritan Pharmaceuticals Inc. (OTC BB:SPHC) | CHDI Foundation Inc. | Nonexclusive licensing agreement | To six of Samaritan's Alzheimer's drugs | CHDI will evaluate the drugs over 18 months as possible Huntington's disease therapeutics; CHDI will pay for the cost of that evaluation, and Samaritan retains all rights to the compounds (1/24) |
| Seaside Therapeutics* | Vanderbilt University Medical Center | Collaborative research contract | To discover compounds to potentially suppress the manifestations of fragile X syndrome | Seaside awarded the $4.5M to the university, which has identified more than 400 novel compounds belonging to multiple chemical classes that inhibit mGluR5 (2/4) |
| Science Applications International Corp. (NYSE:SAI) | National Institute of Allergy and Infectious Diseases' Division of Microbiology and Infectious Diseases | Contract extension | To provide malaria vaccine production and support services | The seven-year, cost-plus-fixed fee deal has an estimated value of $32.7M, and the contract extension represents a follow-on effort for previous work (11/1) |
| Scynexis Inc.* | Drugs for Neglected Disease initiative (Switzerland) | Five-year research and development collaboration | For therapies to treat human African trypanosomiasis | The $17M partnership includes Genzyme Corp. and Pace University (11/5) |
| SemBioSys Genetics Inc.(Canada; TSX:SBS) | The Instituto de Agrobiotecnologia Rosaria SA (Argentina) | Option agreement | To evaluate the utility of using plant-produced chymosin for the production of cheese in South America | SemBioSys will receive an option fee and will be eligible to collect an up-front license fee, possible milestone payments and royalties (1/29) |
| Serenex Inc.* | CHDI Inc. | Agreement | To evaluate a number of Serenex's Hsp90 inhibitors as potential therapeutics for Huntington's disease | Financial terms were not discclosed, but Serenex will retain all rights to the molecules (1/17) |
| Serenex Inc.* | National Cancer Institute | CRADA | To assess the company's oral, small-molecule, heat-shock protein 90 inhibitor, SNX-5422, in non-small-cell lung cancer | The product is in Phase I testing in cancer (1/24) |
| Singulex Inc.* | Washington University School of Medicine | Collaboration | To increase the clinical utility of validated and recently discovered biomarkers in human disease | The parties will develop bio-marker assays for biomarkers in important disease areas, including breast cancer, Alzheimer's diseases, diabetes and stroke (11/18) |
| Sinovac Biotech Ltd. (China; AMEX:SVA) | Beijing Public Health Bureau | Purchase agreement | For Sinovac's seasonal influenza vaccine Anflu | Terms were not disclosed (10/22) |
| Sirtris Pharmaceuticals Inc. (SIRT) | National Cancer Institute | Collaboration | To test the anticancer impact of Sirtris' SIRTI enzyme activators in numerous models of cancer | The study will include SRT501 and multiple compounds from different chemical classes of Sirtris' new chemical entities (2/21) |
| SRI International* | National Cancer Institute | Contract | To conduct analytical chemistry evaluations of cancer drugs and dosage formulations | The contract is worth $7.9M (10/23) |
| SRI International* | National Institute of Allergy and Infectious Diseases | Contract | To provide preclinical services for developing drugs and therapeutic vaccines for HIV and opportunistic infections associated with HIV/AIDS | The contract is worth $15.5M (11/13) |
| StemCells Inc. (STEM) | Oregon Health & Science University Casey Eye Institute | Collaboration | To evaluate HuCNS-SC as a potential treatment for retinal degeneration | The parties will evaluate engraftment and function of HuCNS-SC cells in the same rat model preparatory to planned clinical trials (1/24) |
| StemCyte Inc.* | Rutgers University | Research and license agreement | For a spinal cord injury therapy that uses StemCyte's human umbilical cord blood stem cells in conjunction with lithium | StemCyte will provide financial sponsorship for work at Rutgers' W.M. Keck Center for Collaborative Neuroscience and will receive exclusive commercialization rights to the therapy; Rutgers is eligible for royalties (2/26) |
| Sunesis Pharmaceuticals Inc. (SNSS) | Multiple Myeloma Research Consortium | Collaboration | To evaluate SNS-032 in multiple myeloma | The consortium will conduct preclinical work to identify bio-markers for use in future clinical development (12/19) |
| SuperArray Bioscience Corp.* | Carnegie Institution | License agreement | To develop, manufacture and distribute RNA interference-based gene function and mechanism-of-action research tools | Financial terms were not disclosed (11/30) |
| Upstream Biosciences Inc. (OTC BB:UPBS) | Combinatorial Chemistry Center of the Chemistry Department of Lomonosov Moscow State University | Collaboration | For the chemical synthesis of novel compounds that Upstream intends to test for efficacy and toxicity against tropical parasitic diseases | The center will provide Upstream with drug candidates for in vivo testing; financial terms were not disclosed (1/9) |
| Upstream Biosciences Inc. (OTC BB:UPBS) | Makerere University (Uganday) | Collaboration | To start in vivo efficacy and toxicity testing of compounds for trypano-somiasis (African sleeping sickness) | Further terms were not disclosed (12/17) |
| Upstream Biosciences Inc. (OTC BB:UPBS) | Provincial Laboratory for Public Health in Alberta | Partnership | To begin in vitro testing of the firm's novel compounds for the potential treatment of malaria | Further terms were not disclosed (1/3) |
| Vermillion Inc. (VRML) | Johns Hopkins University | Collaboration | On the development of novel biomarkers for disease detection, classification and monitoring of prevalent cancers, including ovarian, breast and prostate | Vermillion will have access to exclusive commercial rights to the discoveries made and will continue to provide financial support, technical assistance and access to its advanced technology platforms, while Johns Hopkins will contribute cancer serum samples and clinical and scientific expertise (2/6) |
| Vical Inc. (VICL) | The Wistar Institute | License agreement | Granting Vical exclusive, worldwide rights to Wistar's Towne strain of cytomegalovirus and related technologies | Financial terms were not disclosed (1/22) |
| VioQuest Pharmaceuticals Inc. (OTC BB:VQPH) | National Cancer Institute | Clinical trial agreement | For a trial of VQD-002 in cancer patients | The NCI will sponsor a trial of VQD-002 in combination with erlotinib (2/26) |
| Viral Genetics Inc. (PK:VRAL) | University of Colorado and V-Clip Pharmaceuticals Inc. | Collaboration | For the exclusive worldwide rights to patent applications and know-how in the fields of diagnosing and treating HIV/AIDS, hepatitis C, herpes | Viral Genetics will fund the tests for about $600,000; the agreement includes various royalties and milestone payments (12/20) |
| VIRxSYS Corp.* | National Heart, Lung and Blood Institute | CRADA | Focused on athero-sclerosis | A major aim is to create ways of increasing the level of HDL cholesterol in the bloodstream using VIRxSYS's spliceosome-mediated RNA trans-splicing technology (1/17) |
| Vivalis (France; PARIS:VLS) | Chemo-Sero-Therapeutic Research Institute (Japan) | Extended collaboration | To test Vivalis' EBx cells for the production of human and veterinary viral vaccines | The expanded license covers two additional viruses, one in human disease and one in veterinary medicine (1/29) |
|
Notes: This chart does not include grants or contract awards, or agreements between biotech companies and clinical trial centers. * Denotes privately held company; ** Denotes the date the item ran in BioWorld International.@ Some institutions listed have for-profit components. They are located in the U.S. unless otherwise noted. CRADA = Cooperative Research and Development Agreement.Unless otherwise noted, shares are traded on the Nasdaq exchange. AMEX = American Stock Exchange; BR = Brussels Stock Exchange; CDNX = Canadian Venture Exchange; Frankfurt Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; SSE = Stockholm Stock Exchange; TEL = Tel Aviv Stock Exchange; TSX = Toronto Stock Exchange.v | ||||
To read more on related topics, click on one of the words below.